clinical trial · NCT04857827
A Study to Evaluate Safety and Tolerability of QLS-101 in NTG
Qlaris Bio, Inc.·phase2·completed·n = 30
Normal Tension Glaucoma (NTG)QLS-101Timolol maleate PF 0.5% ophthalmic solution
brief summary
A randomized active-controlled multi-site double-masked 28 day study to evaluate the safety and tolerability of QLS-101 versus timolol maleate Preservative Free (PF) 0.5% ophthalmic solution in subjects with normal tension glaucoma
started
Sep 15, 2021
primary completion
Aug 26, 2022
completion
Aug 26, 2022
last updated
Jan 20, 2025
official title
A Randomized Active-controlled Study to Evaluate Safety and Tolerability of QLS-101 Versus Timolol Preservative Free (PF) Ophthalmic Solution in Subjects With Normal Tension Glaucoma (NTG)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol